403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Investing In Independence: Brazil’S Push For Healthcare Self-Sufficiency
(MENAFN- The Rio Times) (Analysis) Brazil's Health, Economic, and Industrial Complex (HEIC) significantly impacts its economy, contributing about 10% of the GDP and employing nine million people.
Recognizing the sector's potential, the government is injecting between R$42 billion ($7.64 billion) and R$60 billion ($10.91 billion) into healthcare by 2026. The aim is to bolster innovation and reduce foreign dependence.
The urgency of this initiative became clear when the COVID-19 pandemic highlighted severe vulnerabilities due to the lack of domestic production.
Brazil's health trade deficit worsened from US$16 billion in 2020 to US$21.5 billion in 2021. This increase highlights the urgent need for local manufacturing.
The plan includes increasing domestic production of health products from 42% to 70% within ten years. It focuses on essential medicines and equipment used by the public health service.
Local production has already shown its value during the pandemic. Significant advancements in vaccine manufacturing have been made at institutions like Fiocruz and the Butantan Institute.
Additionally, recent investments have expanded capabilities, as exemplified by the opening of a new biotechnology facility in Pernambuco.
Strengthening Brazil's Health Sector
Financial backing is robust, with the Brazilian Development Bank (BNDES ) allocating over R$2 billion ($363.64 million) in 2023 to health-related manufacturing-a 64% increase from the previous year.
These investments support high-tech health solutions, including mRNA vaccines and other biotech products.
They are crucial for tackling an aging population and diverse health challenges such as infectious diseases and chronic conditions.
Through these efforts, Brazil aims to strengthen its position in the global health industry and reduce its reliance on imported goods. This will help secure a more resilient future for its healthcare system.
The strategy focuses on immediate needs. It also sets the stage for Brazil to become a leader in health innovation and production on the international stage.
Recognizing the sector's potential, the government is injecting between R$42 billion ($7.64 billion) and R$60 billion ($10.91 billion) into healthcare by 2026. The aim is to bolster innovation and reduce foreign dependence.
The urgency of this initiative became clear when the COVID-19 pandemic highlighted severe vulnerabilities due to the lack of domestic production.
Brazil's health trade deficit worsened from US$16 billion in 2020 to US$21.5 billion in 2021. This increase highlights the urgent need for local manufacturing.
The plan includes increasing domestic production of health products from 42% to 70% within ten years. It focuses on essential medicines and equipment used by the public health service.
Local production has already shown its value during the pandemic. Significant advancements in vaccine manufacturing have been made at institutions like Fiocruz and the Butantan Institute.
Additionally, recent investments have expanded capabilities, as exemplified by the opening of a new biotechnology facility in Pernambuco.
Strengthening Brazil's Health Sector
Financial backing is robust, with the Brazilian Development Bank (BNDES ) allocating over R$2 billion ($363.64 million) in 2023 to health-related manufacturing-a 64% increase from the previous year.
These investments support high-tech health solutions, including mRNA vaccines and other biotech products.
They are crucial for tackling an aging population and diverse health challenges such as infectious diseases and chronic conditions.
Through these efforts, Brazil aims to strengthen its position in the global health industry and reduce its reliance on imported goods. This will help secure a more resilient future for its healthcare system.
The strategy focuses on immediate needs. It also sets the stage for Brazil to become a leader in health innovation and production on the international stage.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment